Analyst Price Targets — QTRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 22, 2025 12:00 pm | — | Canaccord Genuity | $8.00 | $6.59 | TheFly | Quanterix price target raised to $8 from $5 at Canaccord |
| March 25, 2025 1:35 pm | Sung Ji Nam | Scotiabank | $18.00 | $7.02 | TheFly | Quanterix price target lowered to $18 from $28 at Scotiabank |
| June 11, 2024 7:54 am | Sung Niam | Scotiabank | $32.00 | $18.50 | StreetInsider | Scotiabank Reiterates Sector Outperform Rating on Quanterix Corp. (QTRX) |
| May 8, 2024 1:42 pm | Kyle Mikson | Canaccord Genuity | $25.00 | $16.51 | TheFly | Quanterix growth potential not reflected in shares, says Canaccord |
| November 10, 2022 10:12 am | — | Goldman Sachs | $13.00 | $11.72 | Benzinga | Goldman Sachs Maintains Neutral on Quanterix, Lowers Price Target to $13 |
Latest News for QTRX
Quanterix Corporation (QTRX) Q4 2025 Earnings Call Transcript
Quanterix Corporation (QTRX) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.3 per share a year ago.
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter and full year ended December 31, 2025. “I am thrilled to be joining Quanterix at a time when the company is well-positioned to deliver long-term growth,” said Everett Cunningham, President & CEO of…
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a partnership with Life Line Screening (LLS), a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in…
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March: 46th Annual TD Cowen Healthcare Conference Format: Fireside chat and one-on-one meetings Date: Wednesday, March 4, 2026 Time:…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for QTRX.
U.S. House Trading
No House trades found for QTRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.